5 Stocks With Recent Price Strength Buoyed by a Strong August

U.S. stocks ended August with gains—Dow up >1% (fifth straight monthly win), S&P 500 +2.6%, and Nasdaq +3.9%—and both the S&P 500 and Nasdaq posted their first monthly advance since May, alongside new all-time highs in early August. The article screens for momentum stocks near 52-week highs using criteria including 4-week price gains >0, 12-week gains >10, and Zacks Rank #1/strong broker ratings, then highlights five names with sharp 4-week rallies: EDRY +109.3%, RCMT +42.9%, ASMB +38.4%, DCTH +31.3%, and NESR +23.4%, with reported expected earnings growth of >100% for four of them.

Analysis

This screen is less a fundamentals discovery set than a momentum/estimate-revision basket, which matters because the edge is usually short-lived and concentrated in the most reflexive names. EDRY and NESR are the cleanest cyclical expressions: if freight and upstream capex stay firm, both can keep squeezing higher because small caps with improving revisions often see multiple expansion before earnings catch up. RCMT is more of a cash-flow/contracting story; the upside is steadier, but it is also the least exciting if the market rotates back toward quality and away from beta.

The real second-order effect is that ASMB and DCTH may be trading more like financing-sensitive biotech momentum than pure operating businesses. In that setup, price strength can persist for weeks, but a single failed readout, delay, or capital raise can unwind the move faster than the screen can justify it. If risk appetite weakens, these names should underperform XBI because the market will stop paying for revision momentum and start valuing dilution probability.

Contrarian view: the consensus is likely over-crediting the signal quality of a 4-week rally in very small caps. The move is probably strongest in the next 1-3 weeks if passive and quant flows continue, but the 1-3 month catalyst path is thin unless the next earnings print or guidance confirms the revisions. What would falsify the thesis is a reversal in commodity freight/oil-service activity, a risk-off tape that hits microcaps first, or any earnings/guidance reset that shows the estimates were simply too low, not truly improving.

Key Decisions for Investors

• Tactically long NESR on a modest pullback, targeting a 4-6 week continuation trade; use a tight stop below the prior breakout level because the setup is momentum-driven rather than valuation-supported.
• Prefer RCMT over the more speculative names as the highest-quality momentum expression; pair it versus IWM if you want to isolate small-cap alpha without taking a broad index view.
• Do not chase ASMB or DCTH here; treat both as watchlist names only until there is a verifiable catalyst. If forced to express upside, use small call spreads rather than common stock because the downside from dilution/clinical disappointment is asymmetric.
• For EDRY, wait for confirmation from freight-rate data before adding size; if spot shipping indicators roll over, fade the move rather than buy strength.
• If market breadth weakens or XBI/biotech small caps lose leadership, cut exposure first in ASMB and DCTH, then RCMT; keep NESR/EDRY only if commodity-linked proxies remain firm.